{"id":"NCT01371825","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency","officialTitle":"An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-05-04","primaryCompletion":"2018-01-03","completion":"2018-01-03","firstPosted":"2011-06-13","resultsPosted":"2016-04-18","lastUpdate":"2019-01-30"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lysosomal Acid Lipase Deficiency","Wolman Disease"],"interventions":[{"type":"DRUG","name":"Sebelipase alfa (SBC-102)","otherNames":[]}],"arms":[{"label":"Open-Label Sebelipase Alfa","type":"EXPERIMENTAL"}],"summary":"This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency. Eligible participants received once-weekly (qw) infusions of sebelipase alfa for up to 5 years.","primaryOutcome":{"measure":"Percentage Of Participants In The Primary Efficacy Analysis Set (PES) Surviving To 12 Months Of Age","timeFrame":"Month 12","effectByArm":[{"arm":"Open-Label Sebelipase Alfa","deltaMin":67,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":7,"countries":["United States","Egypt","France","Ireland","United Kingdom"]},"refs":{"pmids":["28179030"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":9},"commonTop":["Vomiting","Diarrhoea","Pyrexia","Rhinitis","Nasopharyngitis"]}}